Lactiplantibacillus sp. LP03 alleviates pulmonary fibrosis by modulating gut microbiota and elevating host palmitoylethanolamide to suppress TGF-β1/Smad2/3-mediated EMT
Laboratory studyOther animals
- Design
- Laboratory study
- Subjects
- Bleomycin-induced mouse model of pulmonary fibrosis
- Dose used in the study
- Oral PEA supplementation (dose not stated in the abstract); Lactiplantibacillus sp. LP03 and other probiotic strains tested separately
- Duration
- Not stated in the abstract
- What was measured
- Mortality, systemic inflammation, lung coefficient, interstitial thickening, collagen deposition and epithelial-to-mesenchymal transition (EMT) markers; gut microbiota composition; serum metabolomics; PEA's independent effect in vivo and in vitro
What the authors reported
The probiotic strain LP03 reduced mortality, inflammation, lung thickening, collagen deposition and EMT in bleomycin-treated mice, restored gut microbial balance (notably increasing beneficial genera such as Ligilactobacillus and Akkermansia) and raised serum PEA. Oral PEA supplementation on its own also reduced fibrosis, acting by suppressing TGF-beta1/Smad2/3 signalling and EMT.
Limits of this study
A mouse model of chemically induced pulmonary fibrosis; it cannot show effect in people with pulmonary fibrosis. The authors declare no competing interests.
Source
PubMed 40994978 · doi:10.3389/fmicb.2025.1659142
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.